Collegium Pharmaceutical Inc

Insider sale: John Freund sells 20 shares of Collegium Pharmaceutical. Small move, but reveals confidence in the company’s CNS & respiratory pipeline and value‑driven outlook. Click for details.

Insider buying at Collegium Pharmaceutical signals confidence after the annual meeting, hinting at future catalysts while highlighting short‑term risks.

Collegium Pharmaceutical insider Garen Bohlin’s May 2026 trades signal confidence in the new AZSTARYS acquisition and a balanced, opportunistic outlook for the company’s evolving ADHD portfolio.

Collegium’s $650 M AZSTARYS acquisition sparks modest insider selling, yet signals confidence in future earnings growth and strategic cross‑selling potential.

Collegium insider sales reveal a cautious, strategic 10b‑5‑1 plan amid recent price drops – investors should watch for future selling trends and upcoming pipeline milestones.